Introduction
Sensitive detection of proteins has become a critical need for proteomics and clinical diagnostics. Typically, a protein assay is performed using an antibody-based immunoassay system, in which the protein targets are specifically bound by their antibodies, and then the binding event is detected via some signal-reporting labels. In general, high-sensitivity immunoassay labels involve the use of certain signal amplification strategies by which a single signal-reporting tag is able to incorporate numerous detectable elements.
Typical high-sensitivity immunoassay tags include enzymes, 1 or their polymeric forms, 2 as well as nanoparticles such as gold colloid, 3, 4 dye-doped nanoparticles 5, 6 and quantum dot. 7 Among them, quantum dots have proved to be promising because of their unique advantages: comparable size to proteins, size-tunable optical properties, stability, and narrow emission bandwidths. Functionalized quantum dot conjugates have been widely used in imaging, targeting and bioanalytical assays.
Stable, water-soluble quantum dots are especially suitable for surface modification with various biomolecules, such as peptides, oligonucleotides, and proteins. [8] [9] [10] [11] DNAzymes are DNA molecules that display catalytic activity, which can be obtained through combinatorial biology methods, such as a systematic evolution of ligands by exponential enrichment (SELEX) or in vitro selection. [12] [13] [14] [15] [16] A number of DNAzymes that are highly specific for Pb 2+ , [17] [18] [19] Cu 2+ , [20] [21] [22] Zn 2+ , 23 and Co 2+ 24,25 have been obtained. Most DNAzymes can be denatured and renatured many times without losing their binding ability or activity. They are relatively less expensive to produce, and more resistant to hydrolysis. Because of the above mentioned favorable properties, DNAzymes have been used as components for DNA-based logic gates 26 and biosensors. [27] [28] [29] DNAzymes are particularly attractive as a platform for designing biosensors. DNAzyme-based metal ion biosensors based on a wide variety of signaling transduction mechanisms, such as fluorescence, colorimetry, and electrochemistry, have also been developed. Here, we describe our development of a highly selective and sensitive immunosensing platform for convenient, cost-efficient fluorescent detection. In this system, antibody-functionalized PbS nanoparticles and a Pb 2+ specific DNAzyme are used as an amplification element and signal-transducing element, respectively. The Pb 2+ specific DNAzyme was selected because of its relatively high enzymatic cleavage efficiency and specificity over Cu 2+ , Zn 2+ and Co 2+ specific DNAzymes, which can provide higher detection sensitivity over other metal ions. The DNAzyme enzyme strand with a quencher is hybridized to a substrate strand with a fluorophore. Firstly, a specific immunoreaction takes place in the polystyrene microtiter plate to form sandwich complexes of the antibody-target proteinantibody functionalized PbS nanoparticles. After an aciddissolution step, Pb 2+ samples are obtained. In the prescence of Pb 2+ , the substrate strand is cleaved by the Pb 2+ -specific DNAzyme strand, and the release of a cleaved fragment containing fluorophore results in a significant fluorescence increase. To demanstrate this strategy, human IgG is chosen as a model analyte. The developed strategy can provide a simple, cost-efficient and easy-to-operate immunosensing platform for the detection of target protein with high sensitivity and selectivity. This paper reports a highly sensitive fluorescent immunoassay for the detection of human immunoglobulin G based on PbS nanoparticles and DNAzyme. A sandwich immunoassay format was performed on a microtiter plate. Goat anti-human IgG was coated onto the polystyrene microtiter plate. The human IgG analyte was first captured by the goat anti-human IgG, and then sandwiched by a goat anti-human IgG antibody labeled with PbS nanoparticles. After being dissolved with HNO3, the released Pb 2+ made the substrate chain of the DNAzyme labeled with the fluorophore dissociate from the enzyme strand of the DNAzyme labeled with the quencher, which resulted in fluorescence recovery. Then, the human IgG could be detected indirectly from the fluorescent signals. Under the optimized conditions, the linear range of the developed immunosensor was from 1 ng mL -1 to 10 μg mL -1 with a detection limit of 0.8 ng mL -1 . This immunosensor could be used to detect the amount of human IgG in human serum samples. 
Experimental

Reagents and apparatus
Bovine serum albumin (BSA), human immunoglobulin G (IgG) antigen, goat anti-human IgG were purchased from Dingguo Biotechnology Co., Ltd. (Beijing, China). Sodium bis(2-ethylhexyl)sulfosuccinate (AOT), cysteamine, sodium 2-mercaptoethane sulfonate, N-hydroxysulfosuccinimide (Sulfo-NHS), 11-mercaptoundecanoic acid, and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) were purchased from Sigma-Aldrich Chemical Co. (USA). Sodium sulfide, lead acetate, n-heptane, pyridine, methanol and phosphate buffer saline (PBS) were purchased from Sangon Biotech Co., Ltd. (Shanghai, China). Trishydroxymethyl aminomethane (tris) was from Roche (Basel, Switzerland). All solutions were prepared using ultrapure water, which was obtained through a Millipore Milli-Q water-purification system (Billerica, MA), and had an electric resistance > 18.2 MΩ. Serum samples were provided by Hunan Provincial Xiangya Hospital (Changsha, China).
An IgG chemiluminescent immunoassay (CLIA) kit was purchased from Autobio Co., Ltd. (Zhengzhou, China). DNA oligonucleotides were obtained from Life Invitrogen Co., Ltd. (USA), and had the following sequences: Substrate chain: 5′-FAM-TCACTrAGGAAGAGATGATG-3′, Enzyme chain: 5′-CATCATCTCTGAAGTAGCGCCGCCGTA-GTGA-DABCYL-3′. The thermodynamic parameters of all oligonucleotides were calculated using bioinformatics software (http://www.bioin-fo. rpi.edu/applications/), and no particular secondary structures were found for the synthesized oligonucleotide sequences. Fluorescence measurements were performed with an F-7000 fluorscence spectrometer (Hitachi, Japan).
Preparation of PbS nanoparticles
PbS nanoparticles were prepared according to a reported method with some modifications. 30, 31 Briefly, an AOT/n-heptane water-in-oil microemulsion was prepared by the solubilization of 4 mL of distilled water in 200 mL n-heptane in the presence of 14.0 g of AOT surfactant. The resulting solution was separated into two sub-volumes of 120 and 80 mL. Then, 0.32 mL of a 1.0 M Na2S solution and 0.48 mL of a 1.0 M Pb(NO3)2 solution were added into the 80 and 120 mL subvolumes, respectively. The sub-volumes were stirred for 1 h separately, then mixed and stirred for an additional hour under nitrogen to yield PbS nanoparticles. Subsequently, cysteamine (0.34 mL, 0.32 M) and sodium 2-mercaptoethane sulfonate (0.66 mL, 0.32 M) were added, and the mixture was stirred for 24 h under nitrogen. The resulting nanoparticles were obtained by evaporating the n-heptane in a vacuum, and the residue was washed successively with pyridine, hexane and methanol. As a result, PbS nanoparticles were obtained.
Preparation of an antibody labeled with PbS nanoparticles
The PbS nanoparticles were first functionalized with carboxy groups by mixing 6.0 mg of PbS nanoparticles with 600 μL of 11-mercaptoundecanoic acid (0.1 M in 4:1 v/v ethanol:water) for 30 min in a thermostat air bath (37 C). Then, the mixture was centrifuged at 13000 rpm for 10 min, and the sediments were resuspended in 120 μL of PBS buffer solution (20 mM, pH 8.6). Sequentially, the carboxy groups of PbS nanoparticles were activated by treating with 2 mg EDC and 2 mg Sulfo-NHS in 500 μL 10 × diluted suspension at 37 C. After being stirred for 30 min, the mixture was centrifuged at 13000 rpm for 10 min to remove any excess activating substance, and the sediments were redispersed in 1.25 mL of PBS (20 mM, pH 8.6). Finally, the activated PbS nanoparticles were incubated with 1.25 mL of 1 mg mL -1 goat anti-human IgG for 1 h at 37 C. Being blocked by 2 mg mL -1 BSA, the PbS nanoparticles labeled with goat anti-human IgG antibody (PbS-anti-IgG) were collected and centrifuged at 13000 rpm for 10 min, and the sediments were resuspended in 2.5 mL of PBS (10 mM, pH 7.4). The stability of the antibody-functionalized PbS nanoparticles was good, and they could be used for one month when stored at 4 C.
Immunoassay
First, 100 μL of goat anti-human IgG antibody of a concentration of 0.1 mg mL -1 in a carbonate buffer solution (pH 9.6) was pipetted onto a polystyrene microtiter plate, and incubated at 4 C overnight. After removal of the liquid, the polystyrene microtiter plate was washed with PB three times, and then incubated with a 100 μL PB-BSA solution (phosphate buffer containing 1 mg mL -1 BSA) for 1 h at 37 C. After being washed with PB, the polystyrene microtiter plate was added with different concentrations of human IgG (100 μL), followed by incubation at 37 C for 1 h, and then washed with PB three times again. The PbS-anti-IgG (100 μL) was added on a microtiter plate and incubated at 37 C for 2 h. The microtiter plate was rinsed with PB and water, respectively. Then, 100 μL of 0.1 M HNO3 was added to the polystyrene microtiter plate and sonicated for 1 h to make sure that the PbS nanoparticles were dissolved to Pb 2+ completely. At last, an appropriate amount of NaOH solution was added to neutralize Pb 2+ samples. Control experiments were performed in a similar manner, but without adding the human IgG.
Measurement of a DNAzyme-based fluorescent biosensor
A Pb
2+
-dependent DNAzyme was first prepared by the hybridization of a substrate chain (1 μM) and enzyme chain (1 μM) at 25 C for 30 min in a PBS solution (10 mM PB, 137 mM NaCl, pH 7.4). Then, 100 nM of DNAzyme and Pb 2+ samples were added in HEPES buffer (50 mM HEPES, 50 mM NaCl, 5 mM MgCl2), and incubated at 37 C for 20 min. Fluorescence measurements were performed with an F-7000 fluorescence spectrometer.
Results and Discussion
Design strategy of a fluorescence immunosensor Figure 1 schematically depicts the assay protocol of a fluorescence immunosensor for the dectetion of human IgG based on PbS nanoparticles and Pb 2+ -DNAzyme. The design of this strategy included two steps. Firstly, goat anti-human IgG was adsorbed on the surface of polystyrene microtiter plates, followed by the addition of a BSA solution to block adsorption sites of the microtiter plates. Human IgG and PbS-anti-IgG were assembled through the immune sandwich reaction. Then, Pb 2+ samples were obtained by adding an appropriate amount of HNO3 to dissolve the PbS nanoparticles. Secondly, in the presence of Pb 2+ , the substrate chain of the DNAzyme was cut off at the site of ribonucleotide rA, and a short chain marked with fluorophore FAM was released, which resulted in fluorescence recovery. Combining the high sensitivity of Pb 2+ -DNAzyme and the release of a large number of Pb 2+ , resulting from the dissolution of PbS nanoparticles, this technique was expected to show a very high detection sensitivity. Figure 2 depicts the fluorescent spectra of the immunoassay in the presence of 10 μg mL -1 human IgG, PBS buffer, and 100 μg mL -1 BSA. It was observed that in the presence of human IgG target, a well-defined fluorescence emission peak was achieved with a maximum at 518 nm (curve a), a typical fluorescence emission spectrum for FAM labels. In contrast, a very small fluorescent emission peak was obtained in the absence of human IgG (curve b), or in the presence of an excess amount of another protein, such as 100 μg mL -1 BSA, commonly used as a control protein in immunoassay (curve c). These observations conveyed that the fluorescence immunoassay based on PbS nanoparticles and DNAzyme gave a specific response to the human IgG target, and that the nonspecific background response to coexisting proteins was desirably low. In addition, the use of the FITC-labeled antibody instead of the PbS nanoparticle-labeled antibody excluded the Pb 2+ -DNAzyme amplification step in the assay. It is clear that such a Pb 2+ -DNAzyme-free assay merely gave a small fluorescent emission peak (curve d). The signal can be amplified by 308% by introducing the Pb 2+ -DNAzyme amplification step. Such an amplifying-ratio was higher than another conventional assay system, such as an enzyme-linked immunosorbent assay.
Proof-of-principle of the fluorescence immunosensor for the dectetion of human IgG
The effect of the concentration of PbS-anti-IgG on the immunosensor
The fluorescence responses were dependent upon the amount of the PbS-anti-IgG. The greater was the amount of the PbS-anti-IgG, the higher was the concentration of the Pb 2+ samples. Thus, a high concentration of the PbS-anti-IgG was expected to yield an enhanced signal. Figure 3 shows the effect of the concentration of PbS-anti-IgG on the immunosensor. The fluorescence intensity increased quickly with increasing concentration of the PbS-anti-IgG when the concentration was below 2.4 mg mL -1 , indicating that the more was the PbS-antiIgG, the higher was the efficiency of the immunoreaction. When the concentration of the PbS-anti-IgG was above 2.4 mg mL -1 , the fluorescence intensity became saturated. Therefore, a PbS-anti-IgG concentration of 2.4 mg mL -1 was used throughout the experiment.
Effect of the immunoreaction time on the immunosensor
The immunoreaction time also had great effect on the fluorescence signal intensity. Thus, the influence of the reaction time on the assay performance was investigated, as shown in Fig. 4 . It was observed that the fluorescence intensity increased with the increasing the reaction time up to 2 h. There was no significant increase in the fluorescence signal after 2 h. Therefore, the optimum reaction time of 2 h was selected for subsequent assays. Figure 5A depicts the fluorescence emission spectra obtained from the immunosensor in response to different human IgG concentrations. It was observed that the fluorescence intensity increased with increasing IgG concentration over the range from 1 ng mL -1 to 10 μg mL -1 . Figure 5B depicts a calibration curve of the immunosensor. On logarithmic scales, the fluorescence intensity at the maximum emission wavelength was found to exhibit a linear correlation to human IgG concentration over a 4-decade concentration range from 1 ng mL -1 to 10 μg mL -1 with a linear correlation coefficient of 0.9948. The fluorescent intensity of five repetitive assays for the blank solution was 854 ± 39, and a detection limit (LOD) as low as 0.8 ng mL -1 was estimated in terms of the 3σ rule, which was comparable with, or lower than, those reported by most sensitive assay methods currently in use for IgG detection, such as an electrochemical immunoassay based on ZnO/chitosan composite (LOD of 1.2 ng mL -1 ), 32 a plasmon resonance scattering immunoassay system (LOD of 1.46 ng mL -1 ), 33 and an immunoassay readout method based on surface-enhanced Raman scattering (LOD of 30 ng mL -1 ). 34 Such a high sensitivity of the immunosensor was attributed to the double signal amplification of the PbS nanoparticles labels and the enzymatic amplification of Pb 2+ -DNAzyme. In addition, the reproducibility of the immunosensor was examined. Under the same experimental conditions, five repetitive assays were detected using 10 μg mL -1 human IgG. A relative standard deviation of 5.6% was obtained, indicating that the presented immunosensor had good reproducibility. Also, this method offered some advantages, such as ease of operation and cost-effectiveness. The total assay time was about 4 h.
Assay performance of the fluorescence immunosensor
The specificity of the immunosensor was also examined using other proteins, such as immunoglobulin A (IgA), immunoglobulin E (IgE), thrombin, prostate-specific antigen (PSA), carcinoembryonic antigen (AFP), commonly present in human serum as well as BSA. About 100-fold concentrations of these proteins were used in the assay. The fluorescence responses of the developed immunosensor to these proteins are shown in Fig. 6 . It was observed that very small fluorescence signals were obtained for these interfering proteins using the presented method. Thus, no significant cross-reactivity was detected for these proteins, implying high specificity of the immunosensor for IgG detection.
IgG detection in human serum samples
The proposed method was further demonstrated for the direct analysis of human serum specimens. Six human serum specimens were obtained from Hunan Provincial Xiangya Hospital (Changsha, China), and determined by the immunosensor as well as a commercialized CLIA kit as a reference. The results are shown in Table 1 . It was observed that the IgG concentrations obtained using the developed method were in good agreement with those determined by a commercial CLIA kit, and the relative deviations were not more than 7.39%. Such deviations were acceptable in common immunoassay practice, since these assays usually involved multistep reactions on a solid surface. Additionally, the correlativity of the proposed method and CLIA is also shown in Fig. 7 . As can be seen, the analytical results given by the proposed method were in satisfactory agreement with those given by the CLIA procedure. This suggested that it was feasible to apply the developed immunosensor to detecting the IgG concentration in human serum samples.
Conclusions
A novel fluorescent immunoassay technique was developed as a versatile platform for ultrasensitive protein detection. This technique offered enormous signal amplification by combining primary amplification via releasing numerous Pb 2+ from PbS nanoparticles, followed by a secondary Pb 2+ -dependent DNAzyme amplification.
Furthermore, this developed immunosensor had some unique advantages, such as a simple preparation procedure, easy manipulation and high sensitivity. It was demonstrated that the technique possessed high specificity and dose-response sensitivity.
Additionally, this novel fluorescent immunoassay can also be extended for the detection of an analyte antigen of low molecular weight in an indirect competitive format by the competitive binding of free antigen of low molecular weight and its protein-conjugate with a fixed amount of antibody, as described in our previous report. 35 By combining the microtiter plate format, this strategy holds great promise as a sensitive, specific, and multiplex technology for protein detection in proteomics and clinical diagnostics. a. The data are given as the average ± SD obtained in three repetitive experiments. As the IgG concentration level of human serum is very high, the human serum specimens have to be diluted to the detection range of fluorescent immunoassay by using phosphate buffer saline solution. Fig. 7 Correlativity of the results measured by the proposed Pb 2+ DNAzyme-based fluorescent immunoassay and the chemiluminescent immunoassay (CLIA).
